简介：Withthebuyer'smarketstrengthening,retailershavebeguntoleadinproductdevelopmentbyintroducingtheirownprivatelabelproducts.Thesuccessofsuchanewproductlaunchreliesontransmissionofdemandinformationalongasupplychain,yetthisnewphenomenonhasbeenlittleresearched.Thispaperattemptstoaddresssuchanissuebymodelingverticalinformationtransmissioninasupplychainconsistingofaretailerandamanufacturer.Theretailerwouldliketointroduceanewprivatelabelproductandknowsthedemandoftheproducttobeeitherhighorlow,whilethemanufactureronlyknowsthepriordistributionofthedemandtype.Thisstudyattemptstofindwhetherawholesale-pricecontractoratwo-parttariffcontractcanfacilitatethemanufacturertoidentifythedemandtype.Theresultsshowthatthetwo-parttariffcontractisalwayseffectiveinrealizinginformationtransmissionaslongastheretailer'sreserveprofitremainswithinareasonablerange.

简介：社会中有这样一群人，他们不一定是达官显贵，不一定是身价过亿，但他们有绅士般的情趣和品位，过着小资的生活，正如很多时候，他们追求的不一定是单纯的奢华，或许是一瓶黑牌威士忌，与好友细细品味；或许是限量生产的BlackLabel服装，赠送女友；

简介：<正>TheCityDiplomacyofShanghaiWiththedevelopmentofglobalization,thebehavioralagentsofdiplomacyarebecomingmoreandmorediversified.Asthecrystallizationofhumancivilizationandthefocalpointsofnationalcommunication,citiesareimportantbehavioralagentsofdiplomacy.Theroleofbehaviorsubjectsofcitieswillbecomeallthemoresignificant,

简介：AnewchemilurninescencelabelN-(β-carboxypropionyl)luminol(CPL)wasusedtolabelsheepanti-humanIgG(SaHIgG).Thelabeledantibodywasstableandcouldbedetectedatleastdownto10-17~10-16mol.Themolarincorporationratiowasestimatedtobe0.26molofCPLpermolofSaHIgG.TherewerenoapparentchangesintheimmunoreactivityofthelabeledSaHIgGandinthequantumefficiencyoftheCPLafterlabeling.

简介：名词短语anaphoricity的知识可能有利地在coreference分辨率被利用绕过非首语重复法的名词短语的决定。然而，它令人吃惊注意到自动地合并的最近的尝试获得了anaphoricity信息进coreference决定系统远离期望。这份报纸在经由一个标签繁殖算法决定名词短语的anaphoricity改进学习底coreference分辨率建议一个全球学习方法。以便在标签繁殖算法消除巨大的计算负担，我们作为批评例子采用加权的支持向量在训练文章代表所有标记anaphoricity的NP例子。另外，二种内核，即，基于特征的RBF(光线的基础函数)有近似匹配的核和卷绕旋转树内核，被探索计算二个名词短语的anaphoricity类似。ACE2003语料库的实验在学习底coreference分辨率在名词短语和它的申请的anaphoricity决心表明我们的方法的大有效性。

简介：Thisletterpresentsalabel-freebiomolecularimagingtechniquebasedonwhite-lightinterferometryandspectraldetection.Themethodmeasuresthicknesschangescausedbyspecificbindingbetweenbiomoleculestodetectthepresenceofcertainanalyte.Aspectrum-shiftingalgorithmisdevelopedtoresolvethethicknessinformationfromthespectrum.Theaxialresolutionoftheexperimentalinstrumentcanreach～1nm,therebyenablingdetectionoftraceamounts(～1ng/mm2)ofproteinsorDNA.ThisletteralsopresentstwoexperimentstoprovethefeasibilityofthemethodfordetectingproteinsandDNAwithoutfluorescentlabeling.

简介：2008年9月24日，label．m2008“闪亮今秋”发型秀在广州国际美博会上举行。最先出场的是在中国美发行业享有盛名的TONIGUY中国北部艺术创作团队。这场由著名美发大师安洋领衔的表演，汇聚了王川、张国朋、高鹏三位培训导师，他们以TONIGUY经典的剪裁技巧，配合label．m时尚前卫的品牌理念，打造出“重金属年代”这一奢华篇章。

简介：Objective:Thepresentstudyaimedtoevaluatethepossibilityofusingcoherentanti-StokesRamanspectroscopy（CARS）microscopytodeterminethespecificmolecularmorphologyofcholesteatomabydetectingthenaturalvibrationalcontrastofthechemicalbondswithoutanystaining.Materialsandmethods:SpecimensfromthemastoidandtympanicmembranewithandwithoutcholesteatomawereanalyzedusingCARSmicroscopy,two-photonexcitedfluorescence（TPEF）microscopy,andthesecondharmonicgeneration（SHG）microscopy.Results:Incholesteatomatissuesfromthemastoid,astrongresonantsignalat2845cm-1wasobservedbyCARS,whichindicatedthedetectionoftheCH2hydro-carbonlipidbondsthatdonotgeneratevisiblesignalsat2940cm-1suggestiveofCH3bondsinaminoacids.Astrongresonantsignalat2940cm-1appearedinanareaofthesamespecimen,whichalsogeneratedabundantsignalsbyTPEFandSHGmicroscopyat817nm,whichwassuggestiveofcollagen.Inthetympanicmembranespecimenwithcholesteatoma,astrongresonantsignalwithcorrugatedmorphologywasdetected,whichindicatedthepresenceoflipids.AstrongsignalwasdetectedinthetympanicmembranewithchronicotitismediausingTPEF/SHGat817nm,whichindicatedcollagenenrichment.TheCARSandTPEF/SHGimageswereinaccordancewiththehistologyresults.Conclusion:TheseresultssuggesttheneedtodevelopanovelCARSmicroendoscopethatcanbeusedincombinationwithTPEF/SHGtodistinguishcholesteatomafrominflammatorytissues.

简介：

简介：<正>1910年,JesseShwayder创立了一家箱包公司,旨在为那些颠簸在旅途的人,制造质量上乘、精细的行李箱。他选择了《圣经》中的人物大力士参孙(Samson)来象征产品坚固耐用的特征,将公司取名为Samsonite。近一个世纪来,Samsonite成了时尚人士熟悉的一个著名箱包品牌。其精巧工艺、优质物料和独特的风格,一直为商旅人士所心仪。日前在外滩18号,Samsonite举行

简介：本研究以甜菜不育系(N9849)及保持系(960766)为材料,采用Label-free、质谱分析、生物信息学分析方法,对甜菜现蕾期的花蕾进行比较蛋白质组学分析。结果表明:不育系与保持系中鉴定到的96个差异蛋白,涉及16个功能组;其中胁迫响应,碳水化合物代谢,花粉发育等功能类别所占比例较大。胁迫响应功能蛋白类的谷胱甘肽-S-转移酶、过氧化氢酶等在不育系中显著低表达,有毒物质及活性氧的清除能力弱,可能导致不育系材料系统发生紊乱导致形成败育。碳水化合物代谢功能蛋白苹果酸脱氢酶,蔗糖合酶等在不育系中表达量较低,碳水化合物代谢强度低,能量代谢匮乏也是致使花粉不育的一个原因。花粉发育相关蛋白Ⅲ型聚酮合酶在保持系中显著高表达,很好地维持了保持系的育性。本研究在蛋白质组学水平为阐述甜菜明雄性不育机理及其利用提供理论依据。

简介：无

简介：Asthewavelengthdivisionmultiplexing(WDM)technologymaturesandthedemandsforbandwidthincrease,survivabilitybecomesmoreandmoreimportantingeneralizedmulti-protocollabelswitching(GMPLS)controlledintelligentopticalnetworks(IONs).Therearegreatintereststostudytheperformanceofrestorabilityunderonecertainconnectionmanagementstrategy.Andstudiesintheproblemofprovidingrecoveryfromlinkfailuresundertwodifferentresourcereservationschemes,forwardreservationprotocols(FRPs)andbackwardreservationprotocols(BRPs),arepresented.Theyareexaminedfromthepointofviewofconnectionblockingprobability,restorabilityandaveragerecoverytime.Thetwodifferentconnectionmanagementschemesandthesurveyofdifferentrecoveryschemesarefirstpresented.Theperformanceoftheserecoverystrategiesisanalyzedandcomparedboththroughtheoreticalanalysisandsimulationresults.ThemainstressedideaisthatusingBRPsgivesthebestperformanceintermsofrestorabilityandblockingprobabilityinrestorableGMPLSnetworks.

简介：无

简介：Therealizationofanefficientopticalsensorbasedonaphotoniccrystalmetasurfacesupportingboundstatesinthecontinuumisreported.Liquidswithdifferentrefractiveindices,rangingfrom1.4000to1.4480,areinfiltratedinamicrofluidicchamberbondedtothesensingdielectricmetasurface.Abulkliquidsensitivityof178nm/RIUisachieved,whileaQ-factorofabout2000givesasensorfigureofmeritupto445inairatbothvisibleandinfraredexcitations.Furthermore,thedetectionofultralow-molecular-weight（186Da）moleculesisdemon-stratedwitharecordresonanceshiftof6nmperlessthanaInmthicksinglemolecularlayer.Thesystemexploitsanormal-to-the-surfaceopticallaunchingscheme,withexcellentinterrogationstabilityanddemonstratesalignment-freeperformances,overcomingthelimitsofstandardphotoniccrystalsandplasmonicresonantconfigurations.

简介：与微分双相编码给调音的振幅移动(D8PSK/ASK)调音的微分8水平阶段移动(DBC)的一种新奇直角的调整格式的原则被介绍。基于它，一个光标记计划，收费载重在是100Gbit/sD8PSK信号和标签是10Gbit/sDBC问信号，被建议并且模仿。结果与另外的当前的计划相比，并且传播的效果变化调整扑灭比率(嗯)并且系统性能上的收到的功率分别地被分析。光谱效率和小点错误评估的结果表演(BER)极大地被改进，并且什么时候调整嗯被增加到11dB，在收费载重和标签之间的平衡表演被完成。

简介：AbstractBackground:Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported evaluation of the efficacy, safety, and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab treatment.Methods:This was a prospective, multicenter, open-label, single-arm, phase 3 study (NCT01596621; C18083/3076) with a 2-year follow-up period. Eligible patients received bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles (and up to eight cycles). The primary endpoint was the overall response rate (ORR); and secondary endpoints were duration of response (DoR), progression-free survival (PFS), safety, and pharmacokinetics. Patients were classified according to their best overall response after initiation of therapy. Proportions of patients in each response category (complete response [CR], partial response [PR], stable disease, or progressive disease) were summarized along with a two-sided binomial exact 95% confidence intervals (CIs) for the ORR.Results:A total of 102 patients were enrolled from 20 centers between August 6th, 2012, and June 18th, 2015. At the time of the primary analysis, the ORR was 73% (95% CI: 63%-81%) per Independent Review Committee (IRC) including 19% CR and 54% PR. With the follow-up period, the median DoR was 16.2 months by IRC and 13.4 months by investigator assessment; the median PFS was 18.6 months and 15.3 months, respectively. The most common non-hematologic adverse events (AEs) were gastrointestinal toxicity, pyrexia, and rash. Grade 3/4 neutropenia was reported in 76% of patients. Serious AEs were reported in 29 patients and five patients died during the study. Pharmacokinetic analysis indicated that the characteristics of bendamustine and its metabolites M3 and M4 were generally consistent with those reported for other ethnicities.Conclusion:Bendamustine is an active and effective therapy in Chinese patients with relapsed, indolent B-cell NHL, with a comparable risk/benefit relationship to that reported in North American patients.Clinical trial registration:ClinicalTrials.gov, No. NCT01596621; https://clinicaltrials.gov/ct2/show/NCT01596621

简介：AbstractBackground:Ciprofol (HSK3486; Haisco Pharmaceutical Group Co., Ltd., Chengdu, China), developed as a novel 2,6-disubstituted phenol derivative showed similar tolerability and efficacy characteristics as propofol when applicated as continuous intravenous infusion for 12 h maintenance sedation in a previous phase 1 trial. The phase 2 trial was designed to investigate the safety, efficacy, and pharmacokinetic characteristics of ciprofol for sedation of patients undergoing mechanical ventilation.Methods:In this multicenter, open label, randomized, propofol positive-controlled, phase 2 trial, 39 Chinese intensive care unit patients receiving mechanical ventilation were enrolled and randomly assigned to a ciprofol or propofol group in a 2:1 ratio. The ciprofol infusion was started with a loading infusion of 0.1-0.2 mg/kg for 0.5-5.0 min, followed by an initial maintenance infusion rate of 0.30 mg·kg-1·h-1, which could be adjusted to an infusion rate of 0.06 to 0.80 mg·kg-1·h-1, whereas for propofol the loading infusion dose was 0.5-1.0 mg/kg for 0.5-5.0 min, followed by an initial maintenance infusion rate of 1.50 mg·kg-1·h-1, which could be adjusted to 0.30-4.00 mg·kg-1·h-1 to achieve -2 to +1 Richmond Agitation-Sedation Scale sedation within 6-24 h of drug administration.Results:Of the 39 enrolled patients, 36 completed the trial. The median (min, max) of the average time to sedation compliance values for ciprofol and propofol were 60.0 (52.6, 60.0) min and 60.0 (55.2, 60.0) min, with median difference of 0.00 (95% confidence interval: 0.00, 0.00). In total, 29 (74.4%) patients comprising 18 (69.2%) in the ciprofol and 11 (84.6%) in the propofol group experienced 86 treatment emergent adverse events (TEAEs), the majority being of severity grade 1 or 2. Drug- and sedation-related TEAEs were hypotension (7.7% vs. 23.1%, P = 0.310) and sinus bradycardia (3.8% vs. 7.7%, P = 1.000) in the ciprofol and propofol groups, respectively. The plasma concentration-time curves for ciprofol and propofol were similar.Conclusions:ciprofol is comparable to propofol with good tolerance and efficacy for sedation of Chinese intensive care unit patients undergoing mechanical ventilation in the present study setting.Trial registration:ClinicalTrials.gov, NCT04147416.

简介：AbstractBackground:This study was to explore the clinical efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection (recombinant human erythropoietin injection, rHuEPO) for the treatment of anemia associated with chronic kidney failure in Chinese patients undergoing hemodialysis.Method:This study was a multicenter, randomized, open-label, intergroup parallel control phase III noninferiority trial from April 19, 2013 to September 9, 2014 at 25 sites. In this study, the members of the darbepoetin alfa group underwent intravenous administration once per week or once every two weeks. The members of the control drug epoetin alfa group underwent intravenous administration two or three times per week. All subjects underwent epoetin alfa administration during the 8-week baseline period. After that, subjects were randomly assigned to the darbepoetin alfa group or epoetin alfa group. The noninferiority in the changes of the average Hb concentrations from the baseline to the end of the evaluation period (noninferiority threshold: -1.0 g/dl) was tested between the two treatments. The time-dependent hemoglobin (Hb) concentration and the maintenance rate of the target Hb concentration (the proportion of subjects with Hb concentrations between 10.0 and 12.0 g/dl) were also evaluated. Iron metabolism, including changes in the serum iron, total iron-binding capacity, ferritin, transferrin saturation, and comparisons of the dose adjustments between the two groups during the treatment period were analyzed further. Adverse events (AEs) were also observed and compared, and the safety was analyzed between the two treatment groups. The conversion rate switching from epoetin alfa to darbepoetin alfa was also discussed. SAS® software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators.Results:Four hundred and sixty-six patients were enrolled in this study, and ultimately 384 cases were analyzed for safety, including 267 cases in the darbepoetin alfa group and 117 cases in the epoetin alfa group. There were 211 cases in the per-protocol set, including 152 cases in the darbepoetin alfa group and 59 cases in the epoetin alfa group. The changes in the average Hb concentrations from the baseline to the end of the evaluation period were -0.07 and -0.15 g/dl in the darbepoetin alfa group and epoetin alfa group respectively. The difference between the two groups was 0.08 g/dl (95% confidence interval [CI]: -0.22 to 0.39), and the lower limit of the 95% CI was -0.22 > -1.0 g/dl. The average Hb concentrations of the two groups were 10.88-11.43 g/dl (darbepoetin alfa) and 10.91-11.38 g/dl (epoetin alfa) during the study period of Weeks 0-28, with the maintenance rates of the target Hb concentration ranging within 71%-87% and 78%-95% in the darbepoetin alfa group and epoetin alfa group respectively. During the period of comparison between the two groups, the incidence of AEs in the darbepoetin alfa group was 61.42%, while in the epoetin alfa group it was 56.41%. All of the adverse events and reactions in the study were those commonly associated with hemodialysis.Conclusion:The overall efficacy and safety of darbepoetin alfa for the treatment of Chinese renal anemia patients undergoing hemodialysis are consistent with those of epoetin alfa.

简介：AbstractBackground:Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods:Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients (n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group (n = 56) and a twice or three times per week intravenous epoetin alfa group (n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS® software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators.Results:The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion:Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.